Synergistic Telomerase-Activating Systems for Enhanced Fertility
Legal Citation
Summary of the Inventive Concept
Integrating telomerase-activating compounds with AI, IoT, blockchain, and nanomaterial technologies to create a comprehensive fertility enhancement platform, enabling personalized fertility monitoring, improved fertility outcomes, and secure fertility preservation.
Background and Problem Solved
The original patent disclosed telomerase-activating compounds for fertility applications, but lacked the integration of advanced technologies to provide a holistic fertility solution. The new inventive concept addresses this limitation by combining telomerase-activating compounds with AI, IoT, blockchain, and nanomaterial technologies to create a more powerful and effective fertility enhancement system.
Detailed Description of the Inventive Concept
The synergistic system comprises a telomerase-activating compound, an AI-powered fertility monitoring device, an IoT-enabled fertility tracking platform, a nanomaterial-based delivery system, and a blockchain-based fertility preservation registry. The AI-powered device provides personalized fertility recommendations based on the subject's telomerase activity, while the IoT-enabled platform tracks fertility metrics and predicts optimal fertility windows. The nanomaterial-based delivery system targets specific fertility-associated cells or tissues, and the blockchain-based registry ensures secure and transparent fertility preservation.
Novelty and Inventive Step
The new claims introduce the integration of telomerase-activating compounds with AI, IoT, blockchain, and nanomaterial technologies, which is not obvious from the original patent. The synergistic combination of these technologies provides a new and non-obvious solution for fertility enhancement.
Alternative Embodiments and Variations
Alternative embodiments may include using different AI algorithms, IoT devices, or blockchain platforms. Variations may include integrating the telomerase-activating compound with other fertility-enhancing technologies, such as gene editing or stem cell therapies.
Potential Commercial Applications and Market
The synergistic telomerase-activating system has significant commercial potential in the fertility industry, with potential applications in in vitro fertilization, fertility preservation, and fertility monitoring. The target market includes fertility clinics, hospitals, and individuals seeking fertility enhancement solutions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/09 |
| A | A61 | A61K31/137 |
| A | A61 | A61K31/4025 |
| A | A61 | A61K31/4545 |
| A | A61 | A61K31/5377 |
| A | A61 | A61K31/66 |
| A | A61 | A61P15/08 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Reproductive medicine, biotechnology, and pharmaceutical compositions with a focus on fertility enhancement and cellular therapies involving telomerase activation
Person of Ordinary Skill (PHOSITA) Profile
A person with advanced degrees in biomedical sciences, molecular biology, or pharmaceutical research, with expertise in reproductive technologies, cell signaling, and drug delivery systems, familiar with interdisciplinary approaches to medical innovation
Obviousness Rationale
A PHOSITA would recognize that integrating telomerase-activating compounds with emerging digital health technologies represents a predictable extension of existing fertility enhancement strategies. The combination of pharmaceutical compounds with AI, IoT, and tracking technologies is a natural progression in personalized medical approaches. The PTD's proposed system builds upon the foundational fertility treatment method disclosed in the source patent by adding technological monitoring and optimization layers.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,516 |
|---|---|
| Title | Telomerase activating compounds for use in fertility and related applications |
| Assignee(s) | Neuromagen Pharma, Ltd. |